The 10K contained many important bits of information regarding events beyond June 30. The terms sheet from August chief among them. This is not a company that surprises to the early side with guidance. When they say it is unlikely to happen I believe them.

At this point it's all about the deal. It is needed to revitalize both the balance sheet, restart clinical trial progress, and restore credibility of guidance from management...all of which are effectively dead.

We have a shelf registration if Aspire is no longer available but due to our terribly low stock price and volume it will not be enough to get the company through a phase 3 trial. I have been wracking my brain going through the numbers and I don't see a way for us to continue, absent a deal on one of our assets, without wiping out the existing share structure.

I don't believe the milestones are in play any longer. We need that deal and we need it soon. All one can do now is pray fortune favors us at the negotiating table.